Co-Diagnostics Reports Continued Strength in Third Quarter 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Wall St slips as higher Treasury yields weigh on sentiment
- Oil pares losses as market weighs Saudi supply concerns, Middle East tensions
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Co-Diagnostics (CODX) Tops Q3 EPS by 17c
November 11, 2021 4:04 PM ESTCo-Diagnostics (NASDAQ: CODX) reported Q3 EPS of $0.38, $0.17 better than the analyst estimate of $0.21. Revenue for the quarter came in at $30.1 million versus the consensus estimate of $24.32 million.
GUIDANCE:
Co-Diagnostics sees FY2021 EPS of $1.07-$1.16, versus the consensus of $0.98. Co-Diagnostics sees... More
